A Multicenter, Open-Label, Single-arm Phase II Study of LP002 in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Latest Information Update: 02 Jun 2023
At a glance
- Drugs LP 002-Lepu Biopharma (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Taizhou HoudeAoke Biomedical
- 02 Jun 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified October 2020).
- 27 Oct 2020 New trial record